Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and h ....Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and hence the risks of dose related side effects. This project has potential both to improve healthcare and to encourage the growth of expertise in the biotechnology industry in Australia.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH190100021
Funder
Australian Research Council
Funding Amount
$4,999,540.00
Summary
ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A ....ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A goal of the Hub is to support the development of new molecular diagnostic technology, improve the processes for identifying potential antibiotic compounds and assess and advise on antimicrobial stewardship with a vision to transform social and health outcomes globally.Read moreRead less
A New Platform for Developing a Compound Against Herpes Simplex Virus. This project aims to further explore the research team’s recent fundamental discovery of a protein found naturally in an Australian abalone that inhibits viral entry by blocking three key viral glycoproteins. We would aim to utilise this knowledge towards development of a new class of therapeutics against Herpes simplex viruses (HSV) and their consequent infections. The new therapeutics could overcome the low bioavailability ....A New Platform for Developing a Compound Against Herpes Simplex Virus. This project aims to further explore the research team’s recent fundamental discovery of a protein found naturally in an Australian abalone that inhibits viral entry by blocking three key viral glycoproteins. We would aim to utilise this knowledge towards development of a new class of therapeutics against Herpes simplex viruses (HSV) and their consequent infections. The new therapeutics could overcome the low bioavailability of current drugs and thus significantly shorten the recurrence period. Such new drugs may have broad applicability.Read moreRead less
Enhancing sunscreen DNA and photo-ageing protection. Skin damage from UV exposure is costly for individuals and the community, particularly in Australia, where the population has predominantly fair skin. While public campaigns to persuade the population to use sun protection and avoidance have been useful, this project will be the first to extend this approach to deliver a way to reduce sun damage from any UV exposure that does nevertheless occur, by incorporating the active agents into topical ....Enhancing sunscreen DNA and photo-ageing protection. Skin damage from UV exposure is costly for individuals and the community, particularly in Australia, where the population has predominantly fair skin. While public campaigns to persuade the population to use sun protection and avoidance have been useful, this project will be the first to extend this approach to deliver a way to reduce sun damage from any UV exposure that does nevertheless occur, by incorporating the active agents into topical sunscreens or creams for after-sun use. The project will also build infrastructure for translational research on photo-damage, combining world-class facilities for this research with advanced formulation and manufacturing operations.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC160100027
Funder
Australian Research Council
Funding Amount
$4,340,802.00
Summary
ARC Training Centre for Biopharmaceutical Innovation. ARC Training Centre for Biopharmaceutical Innovation. This centre aims to transform Australia’s growing biopharmaceutical industry, an advanced manufacturing capability, by training specialist biotechnologists and bioengineers. It expects the research and development outputs will create new biopharmaceuticals and antibody-based reagents, enhanced production methods, improved manufacturing capabilities and a cohort of specialist scientists. Ne ....ARC Training Centre for Biopharmaceutical Innovation. ARC Training Centre for Biopharmaceutical Innovation. This centre aims to transform Australia’s growing biopharmaceutical industry, an advanced manufacturing capability, by training specialist biotechnologists and bioengineers. It expects the research and development outputs will create new biopharmaceuticals and antibody-based reagents, enhanced production methods, improved manufacturing capabilities and a cohort of specialist scientists. New biopharmaceuticals are expected to benefit the Australian economy and provide new therapeutic options for better health outcomes. Industry-driven research projects will also provide industry-ready graduates who can drive future growth in the sector.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC190100026
Funder
Australian Research Council
Funding Amount
$4,969,663.00
Summary
ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway an ....ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway and barriers faced by the sector, namely improving process efficiencies, enabling early-stage scale-up (cell/tissue) and development of the sector's supply chain. The knowledge created and research undertaken would help to accelerate commercialisation in regenerative medicine, tissue engineering and cell therapies.Read moreRead less
Novel technology platform for gene delivery into intact cells. Delivery of DNA to cells is a crucial but highly inefficient process. This project will develop a way to manipulate the genetic code of cells efficiently and to easily generate stem cells from normal adult cells, thus avoiding controversial embryonic harvesting. This new technology will have potential benefits for research, agriculture and humans alike.
Intracellular trafficking and function of a recycling receptor which prolongs the serum half-life of novel therapeutic proteins. The life span of recombinant engineered proteins for therapeutic use is a critical factor in their effectiveness, ease of clinical application and cost. This project will exploit interactions with a natural receptor, which prolongs the lifespan of serum proteins, to enhance survival of therapeutic engineered proteins.